Filing Flows › Standard Biotools (LAB) › Q3 2025
Standard Biotools (LAB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Standard Biotools (LAB) reported revenue of $19.6M for the third quarter 2025 (Q3 2025), -11% from a year earlier and -10% from the quarter before. Operating margin was -168.5%, net loss $34.7M (177.4% of revenue).
Standard Biotools, Q3 2025: revenue $19.6M (-12% year over year), operating margin -168.5%, net loss $34.7M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.6M | -10% | -11% |
| Operating profit | −$32.9M | — | — |
| Net earnings | −$34.7M | — | — |
| Operating cash flow | −$22.2M | — | — |
What changed
Revenue was $19.6M in Q3 2025, down 11% year over year and down 10% from the previous quarter. Consumables was the largest line at 45% of revenue. Consumables lost $1.8M year over year (down 17%), 71% of the total change.
Gross margin was 48.5%, down 6.4 points from a year earlier. Operating costs exceeded revenue by $32.9M, an operating margin of -168.5%. Operating expenses grew 9% against a revenue fall of 11%. The fastest-growing cost line was Other operating costs (+28%). The quarter ended with a net loss of $34.7M, wider than the previous quarter's $33.5M loss.
Operating cash flow was −$22.2M. Non-cash charges added back $1.5M of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $886K exceeded it, leaving free cash flow of −$23.1M.
Questions
What was Standard Biotools' revenue in the third quarter 2025?
Standard Biotools (LAB) reported revenue of $19.6M for the third quarter 2025 (Q3 2025), -11% from a year earlier and -10% from the quarter before.
Was Standard Biotools profitable in the third quarter 2025?
Operating loss was $32.9M (-168.5% of revenue) and net loss $34.7M.
Source: Standard Biotools 10-Q on SEC EDGAR.